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Minimal methylation classifier 
(MIMIC): A novel method for 
derivation and rapid diagnostic 
detection of disease-associated 
DNA methylation signatures
E. C. Schwalbe1,2, D. Hicks1, G. Rafiee1,9, M. Bashton  1, H. Gohlke3, A. Enshaei1, S. Potluri1,  
J. Matthiesen1, M. Mather  1, P. Taleongpong1, R. Chaston4, A. Silmon4, A. Curtis4,  
J. C. Lindsey1, S. Crosier1, A. J. Smith1, T. Goschzik5, F. Doz6, S. Rutkowski7, B. Lannering8,  
T. Pietsch5, S. Bailey1, D. Williamson1 & S. C. Clifford1
Rapid and reliable detection of disease-associated DNA methylation patterns has major potential to 
advance molecular diagnostics and underpin research investigations. We describe the development 
and validation of minimal methylation classifier (MIMIC), combining CpG signature design from 
genome-wide datasets, multiplex-PCR and detection by single-base extension and MALDI-TOF 
mass spectrometry, in a novel method to assess multi-locus DNA methylation profiles within routine 
clinically-applicable assays. We illustrate the application of MIMIC to successfully identify the 
methylation-dependent diagnostic molecular subgroups of medulloblastoma (the most common 
malignant childhood brain tumour), using scant/low-quality samples remaining from the most recently 
completed pan-European medulloblastoma clinical trial, refractory to analysis by conventional 
genome-wide DNA methylation analysis. Using this approach, we identify critical DNA methylation 
patterns from previously inaccessible cohorts, and reveal novel survival differences between the 
medulloblastoma disease subgroups with significant potential for clinical exploitation.
Altered DNA methylation patterns have emerged as a common feature of disease pathogenesis, showing clear 
potential in diagnostics, sub-classification and prediction of therapeutic response/ disease course1–7. In contrast to 
current high-throughput, genome-wide research methodologies (e.g. whole-genome bisulfite sequencing8, DNA 
methylation arrays9), particular challenges exist in the clinical application of disease-associated methylation pat-
terns. These include derivation and validation of representative DNA methylation signatures from genome-scale 
datasets, and their assessment using platform-independent assays that can be applied rapidly to single samples, 
including low quality and/or quantity biopsies, in routine diagnostics. To address this, we have developed and 
validated MIMIC (minimal methylation classifier), a novel polymerase chain reaction (PCR)-based assay for 
the multiplexed assessment of bisulfite-induced methylation-dependent DNA sequence changes10 at multiple 
signature CpG loci. Sequence-specific single-base variants are exposed by primer extension and, here, coupled 
to detection by MALDI-TOF mass spectrometry commonly used in clinical DNA diagnostics11, enabling the 
investigation of samples that were not suitable for analysis using existing methods.
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We focussed assay development on medulloblastoma, the most common malignant brain tumour of childhood12, 
where DNA methylation signatures have clear potential for use in routine clinical sub-classification13,14. 
Medulloblastoma comprises four primary molecular subgroups – WNT, SHH, Grp3 and Grp4 - defined by dis-
tinct methylomic, transcriptomic and genomic features13–15. These subgroups display characteristic clinical fea-
tures, drug targets and outcomes, and have significantly contributed to the 2016 World Health Organisation 
(WHO) classification of brain tumours16. Following design and validation of a MIMIC assay for molecular 
subgrouping, we assessed its efficacy in limited archival tumour biopsies previously refractory to subgrouping 
using current research methods, taken from the pan-European HIT-SIOP-PNET4 medulloblastoma clinical trial 
(2000–2006)17,18. This trial enrolled patients negative for all established clinico-molecular risk-factors (termed 
‘standard-risk (SR)’ disease12), a group for which there is an urgent unmet need to develop biomarker-driven 
treatment strategies.
Results
Derivation of minimal DNA methylation signatures to identify the four medulloblastoma 
molecular subgroups. We first identified a DNA methylation signature of 17 CpG loci, established detec-
tion methods and developed a Support Vector Machine (SVM) classification model for distinction of the four 
medulloblastoma molecular subgroups (WNT, SHH, Grp3 and Grp4; Fig. 1a). Non-negative matrix factorisation 
(NMF) consensus clustering13,19,20 was used to identify subgroup membership of a training cohort comprising 
genome-scale Illumina 450k DNA methylation microarray data for 220 medulloblastomas (Fig. 1b; Fig. 2). The 50 
most discriminatory CpG loci for each subgroup (i.e. 200 in total) were considered as signature candidates. These 
were triaged using (i) a 10-fold cross validated classification fusion algorithm, (ii) a reiterative primer design 
process where amenability to primer design and multiplex bisulfite PCR was assessed in silico (Supplemental 
experimental methods), and (iii) in vitro PCR validation (Fig. 1a; Fig. 3). Candidate signature CpG loci were 
assayed by the development of a novel application of the Agena iPlex assay21, whereby methylation-dependent 
SNPs representative of CpG methylation status were induced by initial treatment of DNA with sodium bisulfite10, 
followed by multiplexed PCR and single base extension of probe oligonucleotides. The resultant products were 
quantified by MALDI-TOF MS (Matrix-assisted laser desorption/ionization-time of flight mass spectrometry; 
Supplementary Fig. 1). The accuracy and precision of methylation estimates from multiplexed extension reactions 
were tested using incremental proportions of bisulfite-treated methylated:unmethylated DNA (Supplementary 
Fig. 2). Using these techniques, our optimal, multiply-redundant 17-CpG locus signature was generated. Finally, 
the training cohort was used to generate an optimised SVM classifier for the signature using 450k DNA methyl-
ation array data.
Development and validation of MS-MIMIC. We next assessed mass spectrometry-minimal methyla-
tion classifier (MS-MIMIC) performance against Illumina 450k methylation microarrays in an independent val-
idation cohort of 106 medulloblastoma DNA samples (Fig. 1c) containing all four medulloblastoma subgroups 
(Supplementary Table 1). DNAs were derived from tissue samples reflecting different clinical fixation methods; 
fresh-frozen biopsies (n = 40), formalin-fixed paraffin-embedded biopsies (FFPE, tumour section; n = 39), or 
FFPE-derived cytospin nuclear preparations18 (n = 27). QC measures for CpG locus-specific assay failure were 
established; up to 6 failed CpGs per sample were tolerated within the multiply-redundant signature/classifier 
without impacting performance and this was the case for 101/106 validation cohort samples (Supplementary 
Figs 3 and 4). A probability threshold for confident subgroup classification was derived empirically, below 
which samples were deemed non-classifiable (6/101 samples; 5.7%) (Supplementary Fig. 5). Respective sub-
group classifications were compared; MS-MIMIC classifications showed complete concordance with the refer-
ence subgroup (as determined by DNA methylation array and/or CTNNB1 mutation status for WNT tumours15; 
Fig. 1d). Furthermore, CpG-level methylation estimates (β-values) were equivalent between methods (R2 = 0.79, 
p < 0.00001; Fig. 1e). As expected, fresh-frozen derivatives performed best (n = 39/40; 98% successfully sub-
grouped), with 92% success (n = 56/61) using FFPE-derived DNA (Fig. 1f–h).
Application of MS-MIMIC to the HIT-SIOP-PNET4 clinical trials cohort. Following successful assay 
development and validation, we next wished to test the application of MS-MIMIC methylation signature detec-
tion in limited, poor quality, archival, clinical biopsies. Analysis of remnant material from the HIT-SIOP-PNET4 
cohort offers the first opportunity to determine the potential utility of molecular subgroup status to predict dis-
ease outcome in a clinical trial of risk-factor negative (SR) medulloblastoma (Fig. 4a, Supplementary Table 2). 
Only FFPE sections (n = 42/153 available tumour samples) and cytospin nuclear preparations (approximately 
30,000 nuclei isolated and centrifuged onto microscope slides18; n = 111/153) remained, whose DNA derivatives 
all fell below quality and quantity thresholds (>200 ng double-stranded DNA (dsDNA)) required for methylation 
profiling using conventional research methods (Illumina 450k and MethylationEpic arrays14). Using MS-MIMIC, 
70% (107/153) of samples were successfully subgrouped, and subgroup assignments and β-value estimations 
were consistent across duplicate determinations (Fig. 4b,c). Assay performance was equivalent across the input 
DNA range (<2 ng (limit of detection) to 100ng dsDNA, 41.4ng median DNA input, p = 0.852, chi-squared test) 
(Fig. 4d,e,f). Reasons for assay failure included unsuccessful bisulfite conversion/PCR (6%; 9/153), and inability to 
classify due to assay QC failure (24%; 37/153) (Fig. 4e). These findings from HIT-SIOP-PNET4 reveal important 
subgroup-dependent molecular pathology in SR medulloblastoma. Grp4 was most common (n = 62; 58%), with 
approximately equivalent numbers of WNT (18/170; 16%), SHH (17/107; 16%) and Grp3 (10/107; 9%) tumours 
observed. As expected, all tumours with CTNNB1 mutations (n = 14) were classified as WNT (Fig. 4g). The 
majority of events (defined as disease recurrence or progression following treatment) observed (11/13) affected 
Grp4 patients (82% 5-year progression-free survival (PFS)), with > 95% PFS in non-Grp4 patients (p = 0.038, 
www.nature.com/scientificreports/
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log-rank test; Fig. 4h). Subgroup assignment will thus be essential to inform future clinical and research studies 
in SR medulloblastoma.
Discussion
We have provided a blueprint for defining minimal, multiply-redundant disease-associated DNA methylation 
signatures from genome-wide datasets, and have developed MS-MIMIC as a validated assay for their assessment, 
including open-source classification tools for data interpretation (http://medulloblastomadiagnostics.ncl.ac.uk; 
Supplementary Fig. 6). Unlike research methodologies (e.g. Illumina 450k and MethylationEPIC arrays) which 
require batched assessments (≥8 samples per run), MS-MIMIC exploits detection technologies in common clin-
ical use (MALDI-TOF) to enable rapid (<3 days from DNA extraction to result), low-cost (<$200 per sample in 
2017), routine assessment in single or multiple samples. The assay format allows a flexible, modular approach, in 
Figure 1. MS-MIMIC, a novel assay to assess minimal DNA methylation signatures, and its application in a 
proof of concept study for the identification of molecular disease subgroups in medulloblastoma. (a) Summary 
of assay design and development including derivation and validation of minimal DNA methylation signatures. 
(b) Non-negative matrix factorisation (NMF) consensus clustering identified four molecular subgroups (WNT, 
SHH, Grp3 and Grp4), defined by four metagenes. (c) Assessing MS-MIMIC performance against 450k DNA 
methylation microarray using 101/106 independent medulloblastoma samples. 5/106 samples failed QC (>6/17 
CpG locus fails). (d) Subgroup classification from MS-MIMIC showed total concordance with the reference 
subgroup (from 450k and GoldenGate DNA methylation arrays and CTNNB1 mutation status) after applying a 
classification confidence probability threshold (NC –non classifiable). (e) Estimates of methylation (β-values) 
using MS-MIMIC assay correlated closely with gold-standard 450k DNA methylation microarray (n = 91). 
(f–h) Subgroup assignment and probability estimates (dots) along with 95% confidence intervals (boxplots) 
for 101 medulloblastoma samples for which DNAs were derived from three types of materials: Fresh frozen 
biopsies (n = 40), formalin-fixed paraffin-embedded biopsies (FFPE, tumour section; n = 35) and FFPE-derived 
cytospin nuclear preparations (n = 26). Samples which did not exceed a classification confidence probability 
threshold of 0.69 (red-line; empirically derived, Supplementary Fig. 5) were deemed nonclassifiable.
www.nature.com/scientificreports/
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which multiplex PCRs can be straightforwardly added or removed, offering the ability to adapt or extend panels 
to evolving clinical needs. Moreover, its low DNA input requirements and applicability to archival sample col-
lections has the potential to unlock previously inaccessible molecular information from informative cohorts, as 
demonstrated for HIT-SIOP-PNET4. This assessment of DNA methylation signatures in the clinical setting holds 
rich promise for molecular sub-classification and prognostication across diverse diseases.
Methods
Cohorts and sample collection. Three cohorts (training; n = 220, validation; n = 106 and test; n = 153) 
were used in this study and are described in Supplementary Table 1. The training and validation cohorts com-
prised archival non-trial medulloblastoma DNA samples and included tumour samples provided by the UK 
Children’s Cancer and Leukaemia Group (CCLG) biobank as part of CCLG-approved biological study BS-2007–
04. The validation cohort consisted of samples with varying DNA quality, to assess assay performance. The test 
cohort included samples from the HIT-SIOP-PNET4 clinical trial (2001–2006)17. All tumours assayed had a con-
firmed histopathological diagnosis of medulloblastoma, with a high tumour cell content. Informed consent was 
obtained from all participants and/or their legal guardians. All experiments were performed in accordance with 
relevant guidelines and regulations.
Identification of a minimal methylation signature for discrimination of medulloblastoma 
molecular subgroups. Non-negative matrix factorisation (NMF) consensus clustering19 was used to iden-
tify the four recognised medulloblastoma consensus molecular subgroups13 using 220 training cohort samples 
run on the Illumina 450k methylation microarray platform (Fig. 2). The 50 most differentially-methylated CpG 
loci for each subgroup were selected as potential signature candidates using limma22. An iterative CpG locus 
selection algorithm was used to select signature gene candidates. To optimise signature loci redundancy in each 
level, up to 6 loci were repeatedly removed at random and classification performance evaluated. The 17 signature 
loci with the highest ranking in classification were identified (Fig. 3).
Figure 2. Derivation of the four consensus medulloblastoma molecular subgroups in a training cohort 
(n = 220) using genome-wide Illumina 450k DNA methylation microarray data. (a) Principal Component 
Analysis (PCA) visualization of groups identified using consensus NMF clustering. Subgroup members are 
shown in their consensus colours (blue (WNT); red (SHH); yellow (Grp3) and green (Grp4)). Covariance 
spheroids were plotted at 95% confidence intervals. (b) Silhouette plot demonstrates robustness of each group 
(number and average silhouette width are shown).
www.nature.com/scientificreports/
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Assay methodology. The MS-MIMIC assay is based on an adaptation of Agena Biosciences’ iPLEX assay 
and the MassARRAY platform21. In order to determine methylation status at each signature CpG locus, bisulfite 
treatment of DNA was used to induce methylation-dependent SNPs. These regions were amplified by multiplex 
PCR, followed by single base extension using mass-modified dideoxynucleotide terminators. MALDI-TOF mass 
spectrometry then identifies the proportions of the induced-SNP alleles, from which methylation status can be 
inferred.
Primer design and validation. PCR and extension primers were designed for multiplex assessment of 
methylation in 17 signature loci (Supplemental experimental methods) across three multiplexes. Plex 1 contained 
an additional bisulfite conversion control, targeting an invariably unmethylated locus which undergoes complete 
conversion to uracil. The multiplexes were validated in vitro using a triplicate mixture series of control DNAs 
ranging from 0–100% methylation (Supplementary Fig. 2). The correlation between the input and estimated 
DNA methylation was calculated, and amplicons with a poor correlation were discarded and replaced with a new 
CpG locus as part of the iterative redesign process (Figs 1a and 3). All signature loci had good linear correlation 
(average correlation coefficient R2 = 0.86.)
Assay implementation. Where possible, 100ng of DNA was bisulfite converted and purified using the 
Qiagen EpiTect Bisulfite kit, according to manufacturer’s protocol. To ensure that template was not too frag-
mented for analysis, a test bisulfite PCR, targeting a 200 bp amplicon, was performed (Supplementary Table 3). 
Figure 3. Derivation of a minimal, multiply-redundant, methylation signature for medulloblastoma subgroup 
identification. Using a three-class (a) and two-class (b) subgrouping model, a minimal multiply-redundant 
methylation signature was identified by selecting a subset of signature candidates with the highest ranking in 
a classifier fusion model (support vector machine (SVM), artificial neural network (ANN), decision tree (DT) 
and Bayesian network (BN). (c) Heatmap of the most discriminatory signature candidates (n = 17) recapitulates 
the four known medulloblastoma subgroups. Chromosomal locations (hg19 assembly) and identifiers of the 17 
CpG loci are reported in the adjacent table.
www.nature.com/scientificreports/
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Figure 4. Application of MS-MIMIC to remnant, archival materials from the HIT-SIOP-PNET4 clinical trial 
cohort enables the first subgroup-specific characterisation of standard-risk medulloblastoma. (a) The HIT-
SIOP-PNET4 clinical trial ran prior to the discovery of medulloblastoma molecular subgroups (2000–2007) and 
remnant tumour sample materials available were old, scant and unsuitable for array-based DNA methylomic 
subgrouping. (b,c) First and second replicates of individual samples show concordance both at the level of 
estimate of methylation (β-value; R2 = 0.59; n = 55 replicates, 17 CpG loci) and subgroup assigment calls (55/55 
replicates; 100%). (d) Bar plot of MS-MIMIC assay input dsDNA amounts. The proportions of samples that 
were successfully subgrouped are shown grey and were consistent across different dsDNA input quantities. Lilac 
represents samples for which subgrouping was not possible due to QC failure in vitro or in classification. (e) 
Proportion of attempted samples (153/161; 95%) successfully subgrouped (107/153; 70%) or failing the assay 
due to failure to 1) bisulfite convert (9/153; 6%) 2) meet QC citerion for CpG-locus specific failure (>6/17 CpG-
locus fails, 24/153 samples; 16%), 3) meet probablility threshold in classification confidence (13/153; 8%). (f) 
Subgroup assignment and probability estimates (dot) along with 95% confidence intervals (boxplots) for 120 
standard risk HIT-SIOP-PNET4 tumours after applying the confidence probability threshold (red-line). (g) All 
samples which were CTNNB1 mutated (CTNNB1mut; a well-established marker of WNT medulloblastoma) were 
assigned as WNT by MS-MIMIC. No non-WNT tumours were CTNNB1mut. (h) Progression free survival (PFS) 
Kaplan-Meier curves for MS-MIMIC derived subgroups reveal that standard-risk Grp4 medulloblastomas show 
a significantly worse disease outcome compared to other subgroups (p = 0.038, log-rank test). Numbers below 
x-axis represent patients at risk of event.
www.nature.com/scientificreports/
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Reaction mixtures and thermal cycling parameters used to amplify the 17 signature loci in multiplex are shown in 
the Supplementary Table 4. Successful amplification was confirmed by gel electrophoresis. The multiplex primer 
iPLEX extension assay was performed as previously described23. Primer sequences for multiplex signature loci 
PCR and iPLEX extension PCR are shown in the Supplementary Table 5 and 6. Mass spectra for the multiplexes 
were acquired on a MALDI-TOF mass spectrophotometer (Voyager DE; PerSeptive Biosystems).
Classifier design and validation. Two support vector machine (SVM) classifier models were created to 
assign subgroup and corresponding probability24, one trained on 450k array data using the 10,000 most var-
iably methylated CpG loci, the second with the 17-CpG locus signature from the training cohort (Fig. 1c). 
Subsequently, 101/106 validation cohort samples were used to assess MS-MIMIC concordance with 450k-derived 
data, at the level of molecular subgroup call (Fig. 1d) and estimates of methylation β-value (Fig. 1e). It was antic-
ipated that when applying MS-MIMIC to poor quality samples, certain loci would not be assessable. Using boot-
strapped datasets (n = 10,000), a threshold of 6 was established for a maximum acceptable number of missing 
loci. Missing loci were imputed using expectation maximisation. Subgroup assignments using MS-MIMIC clas-
sifier were compared against corresponding subgroup calls from the 450k classifier. A threshold for probability of 
assignment by the MS-MIMIC classifier was empirically set to 0.69, below which samples were non-classifiable 
(Supplementary Fig. 5).
Application to HIT-SIOP-PNET4 clinical trial cohort. Following successful assay development and val-
idation, we applied MS-MIMIC to remnant, poor quality, archival, biopsies from the HIT-SIOP-PNET4 clinical 
trial of risk-factor negative medulloblastoma (Fig. 4a, Supplementary Table 2). Only FFPE sections (n = 42/153 
available tumour samples) and cytospin nuclear preparations (approximately 30,000 nuclei isolated and cen-
trifuged onto microscope slides18; n = 111/153) remained, whose DNA derivatives all fell below quality and 
quantity thresholds (>200 ng double-stranded DNA (dsDNA)) required for methylation profiling using conven-
tional research methods (Illumina 450k and MethylationEpic arrays14). We assessed differential survival of the 
MS-MIMIC subgroup assignments using log-rank tests.
Further technical details are provided in the Supplemental experimental methods.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
References
 1. Besingi, W. & Johansson, A. Smoke-related DNA methylation changes in the etiology of human disease. Human molecular genetics 
23, 2290–2297 (2014).
 2. Wahl, S. et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature 541, 81–86 
(2017).
 3. Mehta, D. et al. Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. 
Proceedings of the National Academy of Sciences of the United States of America 110, 8302–8307 (2013).
 4. Ong, M. L. & Holbrook, J. D. Novel region discovery method for Infinium 450 K DNA methylation data reveals changes associated 
with aging in muscle and neuronal pathways. Aging Cell 13, 142–155 (2014).
 5. Bacalini, M. G. et al. Identification of a DNA methylation signature in blood cells from persons with Down Syndrome. Aging 7, 
82–96 (2015).
 6. Portales-Casamar, E. et al. DNA methylation signature of human fetal alcohol spectrum disorder. Epigenetics Chromatin 9, 1–20 
(2016).
 7. Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer 
Cell 22, 425–437 (2012).
 8. Harris, R. A. et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic 
epigenetic modifications. Nat Biotech 28, 1097–1105 (2010).
 9. Bibikova, M. et al. High density DNA methylation array with single CpG site resolution. Genomics 98, 288–295 (2011).
 10. Wang, R. Y., Gehrke, C. W. & Ehrlich, M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine 
residues. Nucleic Acids Research 8, 4777–4790 (1980).
 11. Griffin, T. J. & Smith, L. M. Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry. Trends In Biotechnology 
18, 77–84 (2000).
 12. Pizer, B. L. & Clifford, S.C. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress 
towards biologically driven clinical trials. British Journal Of Neurosurgery 23, 364–375 (2009).
 13. Schwalbe, E. C. et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome 
prediction using formalin-fixed biopsies. Acta Neuropathologica 125, 359–371 (2013).
 14. Hovestadt, V. et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival 
tumour material using high-density DNA methylation arrays. Acta Neuropathologica 125, 913–916 (2013).
 15. Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica 123, 465–472 (2012).
 16. Louis, D. N., Cavenee, W. K., Ohgaki, H. & Wiestler, O. D. WHO classification of tumours of the central nervous system, Edn. 4th 
revised, 184–200 (IARC Press, Lyon; 2016).
 17. Lannering, B. et al. Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk 
Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology 30, 3187–3193 
(2012).
 18. Clifford, S. C. et al. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-
center HIT-SIOP-PNET4 clinical trial. Oncotarget 6, 38827–38839 (2015).
 19. Brunet, J. P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. 
Proceedings of the National Academy of Sciences of the United States of America 101, 4164–4169 (2004).
 20. Hill, R. M. et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically 
targetable disease. Cancer Cell 27, 72–84 (2015).
 21. Gabriel, S., Ziaugra, L. & Tabbaa, D. SNP genotyping using the sequenom massARRAY iPLEX platform. Current Protocols in Human 
Genetics, 2.12.1–2.12.18 (John Wiley & Sons, Inc., 2009).
 22. Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids 
Research 43, e47 (2015).
www.nature.com/scientificreports/
8SCIENTIFIC REPoRTS | 7: 13421  | DOI:10.1038/s41598-017-13644-1
 23. Ross, P., Hall, L., Smirnov, I. & Haff, L. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotech 16, 
1347–1351 (1998).
 24. Chih-Chung, C. & Chih-Jen, L. LIBSVM: A library for support vector machines. ACM Trans Intell Syst Technol. 2(3), 1–27 (2011).
Acknowledgements
This work was supported by Cancer Research UK (Programme grants C8464/A13457 and C8464/A23391; S.C.C., 
D.W. and S.B.) and the UK Children’s Cancer and Leukaemia Group (CCLG)/Tom Grahame Trust (Project grant 
to S.C.C, D.W. and S.B.). The HIT-SIOP-PNET4 clinical trial was supported by Cancer Research UK, Swedish 
Childhood Cancer Foundation, French Ministry of Health/French National Cancer Institute and German 
Children’s Cancer Foundation; informed consent was obtained from all subjects. Tumour investigations were 
conducted with approval from Newcastle and North Tyneside Research Ethics Committee (Study reference 07/
Q0905/71).
Author Contributions
E.C.S., D.H., G.R., and S.C.C. designed and supervised the study and wrote the manuscript. E.C.S., G.R., A.E., M.B. and 
D.W. developed and implemented the in silico methods and computational algorithms. D.H., E.C.S., H.G., S.P., M.M., 
J.M., P.T., J.C.L, S.C. and A.J.S. performed the laboratory experimentation and analysis. R.C., K.S., A.S. and A.C. 
developed the clinical diagnostic test. T.G., F.D., S.R., B.L., T.P. and S.B. provided clinical trial samples, data and 
interpretation. All authors contributed to and approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-13644-1.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
